Last updated: 2026-10-10 11:25:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Artelo Biosciences, Inc. (ARTL) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3,23, with a market capitalization of $1,85M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3,19 to $179,19. This page covers its latest market performance, valuation, price trends and company information.
$1,85M | |
$3,44 | |
$351 280,80 | |
$3,19 | |
$3,37 | |
44,25K | |
488,79K | |
-- | |
$179,19 | |
$3,19 | |
-- | |
-- |
Artelo Biosciences, Inc. (ARTL) last closed at $3,37 as of 2026-10-09 23:51:00, unchanged from the previous close of $3,37.
During the latest regular trading session, ARTL traded between $3,19 and $351 280,80, with a volume of 44,25K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Artelo Biosciences, Inc. (ARTL) moved from $3,83 to $3,23, representing a decline of 15,67% ($0,60).
The stock traded between $3,19 and $4,07 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 58,60 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0,0%
ARTL is currently trading at $3,23, placing it 0,0% of the way from its 52-week low of $3,19 to its 52-week high of $179,19. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 7 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Artelo Biosciences, Inc. (ARTL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.